An interventional study of Home-Based Multicomponent Exercise Program and Microcrystalline Cellulose Control Supplementation in Transthyretin Cardiac Amyloidosis, sponsored by Universidad de Burgos. Completed at 3 sites in Spain. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Universidad de Burgos · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 132 studies in Frailty with a site in Spain — 46 open to participants now, 54 under way, none of them phase 3. Frailty · Spain.
Among the 132 studies in Frailty with a site in Spain, this one is the 72nd largest by enrollment of the 96 interventional ones that give a count, is one of 21 that started in 2026, is one of 93 with no phase, and was the 108th registered.
1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.
Browse Frailty studies →46 of the 132 studies in Frailty with a site in Spain are open now. Recruiting first, the newest first:
Universidad de Granada · Sites in Spain
Ages 65+
University of Vigo · Sites in Spain
Ages 70+
Fundacion Miguel Servet · Sites in Spain
Ages 75+
Alberto Bermejo Franco · Sites in Spain
Ages 70+
Fundación para la Investigación del Hospital Clínico de Valencia · Sites in Spain
Ages 65+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.
This study: 70 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
132 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 21 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is below the median of 83 across 772 interventional studies indexed under Frailty.
Median enrollment 90 across the 96 interventional studies, 432 across the 36 observational. Of the 60 that completed or were terminated, 2 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 132 have an industry lead sponsor. The 10 most frequent:
Universidad de Burgos is the lead sponsor of 25 studies on the registry; 4 are open to participants now.
Universidad de Burgos has 4 studies filed under Frailty — fewer than ten, so there is no comparison to draw.
11 of the studies in Frailty with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04926597Philipp SchuetzEffect of Continued Nutritional Support at Hospital Discharge on Mortality, Frailty, Functional Outcomes and Recovery | 2026-12 |
| NCT06556537Universidad de ZaragozaEffects of Physical Exercise on Frailty, Mental and Physical Health of Older Adults in Rural Areas. | 2026-12-20 |
| NCT07275996Universidad de BurgosNeuromuscular and Multi-Omics Synergy of Combined Creatine × HMB Supplementation Plus Exercise to Improve Muscle Function in Sarcopenic Frailty | 2026-12-30 |
| NCT07643064Alberto Bermejo FrancoMulticomponent Exercise and Comprehensive Geriatric Assessment Program (FRAIL+AP) for Frail Older Adults in Primary Care | 2026-12-31 |
| NCT07848802University of VigoPhysical Function and Fall Risk in Older Adults in the Lalín Frailty Prevention Program | 2027-01-15 |
Add all 11 to your calendar (.ics) → With an account.
Among the 132 studies in Frailty with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Transthyretin cardiac amyloidosis (TTR-CA) is a systemic cardiac disease that predominantly affects older adults and is frequently associated with reduced physical capacity, muscle weakness, frailty, and impaired quality of life. Although disease-modifying treatments can slow cardiac disease progression, functional and nutritional impairment remain important unmet clinical needs.
EFICAC-TTR is a prospective, randomized, multicenter study designed to evaluate the effects of a 12-week home-based multicomponent exercise program combined with nutritional supplementation in adults aged 70 years or older with confirmed TTR-CA.
A total of 47 participants were randomized to one of three parallel groups: (1) usual medical care; (2) a home-based multicomponent exercise program plus microcrystalline cellulose control supplementation; or (3) the same exercise program plus creatine monohydrate (3 g/day) and beta-hydroxy-beta-methylbutyrate (HMB, 3 g/day).
The primary functional outcomes are change in 6-minute walk test distance and handgrip strength from baseline to 12 weeks. Secondary outcomes include body composition, frailty, quality of life, and nutritional and clinical variables. Mechanistic biomarkers are assessed as exploratory outcomes.
The study aims to determine whether combining exercise with nutritional supplementation can improve functional capacity and related health outcomes in older adults with TTR-CA.
Participants were randomized to three parallel study groups. The usual-care group continued standard clinical management without a structured exercise program or study supplementation. Participants in the two exercise groups performed the same 12-week home-based multicomponent exercise program adapted to individual functional capacity.
In addition to exercise, one group received daily microcrystalline cellulose as a control supplement, whereas the experimental group received creatine monohydrate (3 g/day) plus beta-hydroxy-beta-methylbutyrate (HMB, 3 g/day). The supplement comparison was blinded, while the comparison with usual care was necessarily open because of the behavioral intervention. Functional outcomes were assessed at baseline and after 12 weeks.
Biological samples collected at baseline and after the intervention are used for exploratory mechanistic analyses.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received usual medical care for transthyretin cardiac amyloidosis, including routine cardiology follow-up and general lifestyle and nutritional recommendations, without the structured study exercise program or study supplementation.
Other: Usual Care
Participants performed a 12-week home-based multicomponent exercise program and received daily microcrystalline cellulose as the control supplement. The supplement was provided in sachets matched to the supplementation procedure used in the experimental arm.
Behavioral: Home-Based Multicomponent Exercise Program · Dietary Supplement: Microcrystalline Cellulose Control Supplementation
Participants performed the same 12-week home-based multicomponent exercise program and received daily supplementation with creatine monohydrate (3 g/day) and beta-hydroxy-beta-methylbutyrate (HMB, 3 g/day).
Behavioral: Home-Based Multicomponent Exercise Program · Dietary Supplement: Creatine and HMB Supplementation
A 12-week home-based multicomponent exercise program adapted from the Vivifrail model, including strength, balance, mobility, and endurance exercises tailored to individual functional capacity.
Daily oral supplementation with microcrystalline cellulose, used as a nutritionally inert control supplement to match supplementation procedures.
Daily oral supplementation with creatine monohydrate (3 g/day) and β-hydroxy-β-methylbutyrate (HMB, 3 g/day) for 12 weeks.
Standard clinical management for transthyretin cardiac amyloidosis according to routine cardiology practice.
Change in Handgrip Strength
Change in maximal isometric handgrip strength measured in kilograms (kg) using a calibrated handheld dynamometer (best of three attempts for the dominant hand), expressed as the difference between baseline and 12 weeks.
Time frame: Baseline and 12 weeks
Change in 6-Minute Walk Test Distance
Change in walking capacity assessed by the 6-minute walk test, measured as the difference in total distance walked (meters) between baseline and 12 weeks.
Time frame: Baseline and 12 weeks
Change in Fat Mass
Change in total body fat mass measured in kilograms (kg) using multifrequency bioelectrical impedance analysis, expressed as the difference between baseline and 12 weeks.
Time frame: Baseline and 12 weeks
Change in Skeletal Muscle Mass
Change in skeletal muscle mass measured in kilograms (kg) using multifrequency bioelectrical impedance analysis, expressed as the difference between baseline and 12 weeks.
Time frame: Baseline and 12 weeks
Change in Fat-Free Mass
Change in fat-free mass measured in kilograms (kg) using multifrequency bioelectrical impedance analysis, expressed as the difference between baseline and 12 weeks.
Time frame: Baseline and 12 weeks
Change in Phase Angle
Change in phase angle measured in degrees (°) using multifrequency bioelectrical impedance analysis, expressed as the difference between baseline and 12 weeks.
Time frame: Baseline and 12 weeks
Change in Frailty Status Assessed by the FRAIL Scale
Change in frailty status assessed by the FRAIL scale, a 5-item questionnaire with scores ranging from 0 to 5, where higher scores indicate greater frailty, expressed as the difference between baseline and 12 weeks.
Time frame: Baseline and 12 weeks
Change in Short Physical Performance Battery (SPPB) Score
Change in Short Physical Performance Battery (SPPB) total score, ranging from 0 to 12 points, where higher scores indicate better physical performance, expressed as the difference between baseline and 12 weeks.
Time frame: Baseline and 12 weeks
Change in Clinical Frailty Scale (CFS) Score
Change in frailty severity assessed by the Clinical Frailty Scale (CFS), a 9-point ordinal scale ranging from 1 (very fit) to 9 (terminally ill), where higher scores indicate greater frailty.
Time frame: Baseline and 12 weeks
Change in Barthel Index Score
Change in functional independence assessed by the Barthel Index, scored from 0 to 100, where higher scores indicate greater independence.
Time frame: Baseline and 12 weeks
Change in SARC-F Score
Change in sarcopenia risk assessed by the SARC-F questionnaire, with scores ranging from 0 to 10, where higher scores indicate greater sarcopenia risk.
Time frame: Baseline and 12 weeks
Change in Minnesota Living With Heart Failure Questionnaire Score
Change in health-related quality of life assessed by the Minnesota Living With Heart Failure Questionnaire (MLHFQ), with total scores ranging from 0 to 105, where higher scores indicate worse quality of life.
Time frame: Baseline and 12 weeks
Change in Charlson Comorbidity Index
Change in comorbidity burden assessed using the Charlson Comorbidity Index, a weighted index that accounts for the number and severity of comorbid conditions, where higher scores indicate greater comorbidity burden.
Time frame: Baseline and 12 weeks
Exercise Program Adherence
Proportion (%) of prescribed exercise sessions completed, with adequate adherence defined as completion of at least 80% of prescribed sessions.
Time frame: Up to 12 weeks
Supplement Adherence
Proportion (%) of planned supplement doses consumed, with optimal compliance defined as 90-110%.
Time frame: Up to 12 weeks
Change in Mini Nutritional Assessment Short-Form (MNA-SF) Score
Change in nutritional status assessed by the Mini Nutritional Assessment Short-Form (MNA-SF), with scores ranging from 0 to 14 points, where lower scores indicate poorer nutritional status and greater risk of malnutrition.
Time frame: Baseline and 12 weeks
Incidence of Intervention-Related Adverse Events
Number and type of adverse events related to exercise and/or supplementation, classified according to severity and relatedness, collected during the 12-week intervention period.
Time frame: Up to 12 weeks
Rate of Supplement Discontinuation
Proportion of participants who discontinue study supplementation during the intervention period.
Time frame: Up to 12 weeks
Change in Skeletal Muscle Index (SMI)
Change in skeletal muscle index (SMI), expressed as skeletal muscle mass normalized to height squared (kg/m²), measured using multifrequency bioelectrical impedance analysis, between baseline and 12 weeks.
Time frame: Baseline and 12 weeks
Change in Growth Differentiation Factor 15 (GDF-15)
Change in serum GDF-15 concentration (ng/mL) measured by immunoassay.
Time frame: Baseline and 12 weeks
Change in Soluble ST2
Change in serum soluble ST2 concentration (ng/mL) measured by immunoassay.
Time frame: Baseline and 12 weeks
Change in Interleukin-6 (IL-6)
Change in serum interleukin-6 (IL-6) concentration (pg/mL) measured by immunoassay.
Time frame: Baseline and 12 weeks
Change in C-Reactive Protein (CRP)
Change in serum C-reactive protein (CRP) concentration (mg/dL) measured by immunoassay.
Time frame: Baseline and 12 weeks
Change in circulating miR-21 expression
Change in circulating miR-21 expression measured by quantitative PCR, expressed as relative expression (ΔΔCt).
Time frame: Baseline and 12 weeks
Change in circulating miR-29 expression
Change in circulating miR-29 expression measured by quantitative PCR, expressed as relative expression (ΔΔCt).
Time frame: Baseline and 12 weeks
Change in circulating miR-34a expression
Change in circulating miR-34a expression measured by quantitative PCR, expressed as relative expression (ΔΔCt).
Time frame: Baseline and 12 weeks
Change in circulating miR-155 expression
Change in circulating miR-155 expression measured by quantitative PCR, expressed as relative expression (ΔΔCt).
Time frame: Baseline and 12 weeks
Change in PBMC Immune Polarization Profile by Flow Cytometry
Change in the immunophenotypic profile of peripheral blood mononuclear cells (PBMCs) assessed by multiparametric flow cytometry, including the relative abundance of cell populations with M1-like and M2-like phenotypes and their ratio.
Time frame: Baseline and 12 weeks
Change in Pro-inflammatory (M1) Gene Expression Markers
Change in gene expression of predefined pro-inflammatory (M1-associated) markers in peripheral blood mononuclear cells (PBMCs), measured by quantitative PCR and expressed as relative expression (ΔΔCt).
Time frame: Baseline and 12 weeks
Change in Anti-inflammatory (M2) Gene Expression Markers
Change in gene expression of predefined anti-inflammatory/regenerative (M2-associated) markers in peripheral blood mononuclear cells (PBMCs), measured by quantitative PCR and expressed as relative expression (ΔΔCt).
Time frame: Baseline and 12 weeks
Change in Serum Albumin
Change in serum albumin concentration (g/dL) between baseline and 12 weeks.
Time frame: Baseline and 12 weeks
Change in Serum Prealbumin
Change in serum prealbumin concentration (g/dL) between baseline and 12 weeks
Time frame: Baseline and 12 weeks
Change in Vitamin D
Change in serum 25-hydroxyvitamin D concentration (ng/mL) between baseline and 12 weeks.
Time frame: Baseline and 12 weeks
Change in Galectin-3
Change in serum galectin-3 concentration (ng/mL) between baseline and 12 weeks.
Time frame: Baseline and 12 weeks
Change in NT-proBNP
Change in serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration (pg/mL) between baseline and 12 weeks.
Time frame: Baseline and 12 weeks
Change in High-Sensitivity Troponin T
Change in serum high-sensitivity cardiac troponin T concentration (ng/L) between baseline and 12 weeks.
Time frame: Baseline and 12 weeks
Change in Leptin
Change in serum leptin concentration (ng/mL) between baseline and 12 weeks.
Time frame: Baseline and 12 weeks
Change in Adiponectin
Change in serum adiponectin concentration (µg/mL) between baseline and 12 weeks.
Time frame: Baseline and 12 weeks
Change in IGF-1
Change in serum insulin-like growth factor 1 (IGF-1) concentration (ng/mL) between baseline and 12 weeks.
Time frame: Baseline and 12 weeks
Change in Klotho
Change in serum Klotho concentration (pg/mL) between baseline and 12 weeks.
Time frame: Baseline and 12 weeks
Plan to share: Yes — De-identified individual participant data that underlie the results reported in publications will be made available upon reasonable request.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning 6 months after publication and ending 5 years after publication.
Access criteria: Access to de-identified individual participant data will be granted upon reasonable request to the principal investigator. Requests must include a methodologically sound research proposal and will be evaluated for scientific merit and feasibility. Data sharing will require the execution of a data sharing agreement and will comply with applicable data protection and privacy regulations.
Ran from Feb 2026 to primary completion in Sep 2026, 7 months.
Of 514 non-industry interventional studies with no phase under Frailty, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's 7 months is below that.
Counting every sponsor, half of 519 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: start Jun 2026 → Feb 2026, primary completion Apr 2027 → Sep 2026 and completion Sep 2027 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universidad de Burgos